Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.

Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H.

Tumour Biol. 2013 Feb;34(1):565-9. doi: 10.1007/s13277-012-0582-1. Epub 2012 Nov 14.

PMID:
23150178
2.

Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.

Ugurel S, Rappl G, Tilgen W, Reinhold U.

Clin Cancer Res. 2001 May;7(5):1282-6.

3.

Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U.

Cancer. 2001 Jul 15;92(2):369-76.

PMID:
11466692
4.

Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.

Tong HV, Song le H, Hoan NX, Cuong BK, Sy BT, Son HA, Quyet D, Binh VQ, Kremsner PG, Bock CT, Velavan TP, Toan NL.

BMC Infect Dis. 2015 Jan 23;15:25. doi: 10.1186/s12879-015-0754-x.

5.
6.

Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.

Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G.

Cancer Res. 1997 Nov 15;57(22):5073-6.

7.

Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.

Domingo-Domènech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascón P, Mellado B, Molina R.

Tumour Biol. 2007;28(5):264-72. Epub 2007 Oct 26.

PMID:
17962723
9.

Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.

Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H.

Int J Cancer. 2002 Aug 10;100(5):580-5.

10.

Serum bcl-2 and survivin levels in melanoma.

Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E.

Melanoma Res. 2004 Dec;14(6):543-6.

PMID:
15577328
11.

Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.

Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Stieber P, Nagel D, Peterfi A, Steinle A, Salih HR.

Anticancer Res. 2007 Jul-Aug;27(4A):2041-5.

12.

Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.

Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR.

Cancer Immunol Immunother. 2006 Dec;55(12):1584-9. Epub 2006 Apr 25.

PMID:
16636811
13.
14.

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.

Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group.

J Clin Oncol. 2008 Dec 10;26(35):5748-54. doi: 10.1200/JCO.2008.17.5448. Epub 2008 Nov 10.

15.

Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.

Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D.

Anticancer Res. 2000 May-Jun;20(3B):2203-7.

PMID:
10928178
16.

Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.

Bosserhoff AK, Dreau D, Hein R, Landthaler M, Holder WD, Buettner R.

Recent Results Cancer Res. 2001;158:158-68.

PMID:
11092043
17.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G; European Organisation for Research and Treatment of Cancer Melanoma Group.

Eur J Cancer. 2011 Feb;47(3):361-8. doi: 10.1016/j.ejca.2010.10.005. Epub 2010 Nov 17.

PMID:
21087856
18.

Quantification of anti-sperm antibody and soluble MICA/MICB levels in the serum of infertile people of the Li ethnic group in China.

Wei X, Han Z, Ren B, Xiao X, Li F, Lin D, Luo B, Fu X, Li C, Xia H, Yu P.

Int J Clin Exp Med. 2015 Oct 15;8(10):19274-81. eCollection 2015.

19.

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE.

Clin Cancer Res. 2007 Apr 15;13(8):2422-8.

20.

Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy.

Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C.

Melanoma Res. 2002 Aug;12(4):343-8.

PMID:
12170183

Supplemental Content

Support Center